<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376413</url>
  </required_header>
  <id_info>
    <org_study_id>sysubcr001</org_study_id>
    <nct_id>NCT02376413</nct_id>
  </id_info>
  <brief_title>Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients</brief_title>
  <official_title>Prospective Non-randomized Evaluation of Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast-conserving surgery (BCS) is the traditional surgical treatment for early-stage breast&#xD;
      cancer patients. There are evidences indicating that oncoplastic-BCS (displacement technique)&#xD;
      could improve cosmetic outcomes and/or quality of life, and has similar oncological safety as&#xD;
      traditional BCS does. However, there are no prospective trial comparing oncoplastic-BCS vs.&#xD;
      traditional BCS in terms of cosmetic outcomes and oncological safety. In this study, the&#xD;
      investigators are going to address this issue by assigning patients into traditional and&#xD;
      oncoplastic-BCS group, based on their preference.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unavailable to recruit patients.&#xD;
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Harvard/NSABP/RTOG breast cosmesis grading scale</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positivity rate of cavity margin</measure>
    <time_frame>Intraoperatively.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-recurrence free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast Cancer Treatment Outcome Scale (BCTOS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Local Recurrence of Malignant Tumor of Breast</condition>
  <arm_group>
    <arm_group_label>Traditional BCS</arm_group_label>
    <description>Breast-conserving surgery. Modified radical mastectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oncoplastic-BCS</arm_group_label>
    <description>Breast-conserving surgery. Modified radical mastectomy. Oncoplastic-BCS based on surgeon preference and/or tumor location.&#xD;
Superior pedicle mammoplasty / inverted T&#xD;
Superior pedicle mammoplasty / V scar&#xD;
Batwing&#xD;
Inferior pedicle mammoplasty&#xD;
Racquet mammoplasty/radial scar&#xD;
vertical-scar mammoplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast surgery</intervention_name>
    <description>Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy</description>
    <arm_group_label>Oncoplastic-BCS</arm_group_label>
    <arm_group_label>Traditional BCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy or endocrine therapy or Trastuzumab therapy</intervention_name>
    <arm_group_label>Oncoplastic-BCS</arm_group_label>
    <arm_group_label>Traditional BCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <arm_group_label>Oncoplastic-BCS</arm_group_label>
    <arm_group_label>Traditional BCS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Non-metastatic breast cancer patients received surgical treatment in Sun Yat-sen Memorial&#xD;
        Hospital, Sun Yat-sen University. Informed consent must be obtained for all of the included&#xD;
        patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
          -  ECOG&lt;=2&#xD;
&#xD;
          -  Non-metastatic breast cancer patients with unilateral breast cancer confirmed by&#xD;
             pathology.&#xD;
&#xD;
          -  Operable or operable after neoadjuvant chemotherapy.&#xD;
&#xD;
          -  Extensive, diffuse micro-calcifications on mammography before surgery&#xD;
&#xD;
          -  No history of breast surgery or breast radiation therapy before.&#xD;
&#xD;
          -  Able to follow the standard of care in adjuvant chemotherapy, radiation therapy,&#xD;
             endocrine therapy and targeted therapy after surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multifocal/multicentric diseases noticed before surgery.&#xD;
&#xD;
          -  Inflammatory breast cancer or invasive micro-papillary carcinoma of the breast&#xD;
             confirmed by pathology before surgery.&#xD;
&#xD;
          -  Tumor size &gt; 5 cm revealed by physical examination, Ultrasound or mammography before&#xD;
             surgery.&#xD;
&#xD;
          -  Tumor size/breast size ratio &gt;0.5 revealed by by physical examination, Ultrasound or&#xD;
             mammography before surgery.&#xD;
&#xD;
          -  Have other malignant tumors.&#xD;
&#xD;
          -  Have severe co-morbidities that compromise the patients' compliance to our protocol,&#xD;
             or endanger the patients.&#xD;
&#xD;
          -  Participated in other clinical trials.&#xD;
&#xD;
          -  Pathologically confirmed metastatic breast cancer, bilateral breast cancer or DCIS&#xD;
             patients.&#xD;
&#xD;
          -  Patients with any organ failure.&#xD;
&#xD;
          -  Pregnancy women&#xD;
&#xD;
          -  Patients who desire to have mastectomy before surgery.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erwei Song, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen Memorial Hospital,Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fengxi Su, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Yat-sen Memorial Hospital, Sun Yat-sen University.</affiliation>
  </overall_official>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Erwei Song, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Morbidity</keyword>
  <keyword>The Breast Cancer Treatment Outcome Scale</keyword>
  <keyword>Disease free survival</keyword>
  <keyword>Positivity cavity margin rate</keyword>
  <keyword>Harvard/NSABP/RTOG breast cosmesis grading scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

